Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/1...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Br J Haematol
المؤلفون الرئيسيون: Marchesini, Gessica, Nadali, Gianpaolo, Facchinelli, Davide, Candoni, Anna, Cattaneo, Chiara, Laurenti, Luca, Fanci, Rosa, Farina, Francesca, Lessi, Federica, Visentin, Andrea, Marchesi, Francesco, Prezioso, Lucia, Spolzino, Angelica, Tisi, Maria Chiara, Trastulli, Fabio, Picardi, Marika, Verga, Luisa, Dargenio, Michelina, Busca, Alessandro, Pagano, Livio
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley and Sons Inc. 2020
الموضوعات:
Haematological Malignancy – Clinical
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246914/
https://ncbi.nlm.nih.gov/pubmed/33058237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.17145
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة